Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial

Table 7 Change in eGFR [the final evaluation point^a/W0 (week 0 of the treatment period)] analyzed by the ANCOVA model

Treatment group	Number of patients	Least square mean of the difference in serum cystatin C (mg/L)		Difference in the least square mean (versus placebo) (mg/L)		P-value
Treatment group	Number of patients	Point estimate	SE	Point estimate	SE	P-value
Placebo	34	0.877	0.025	―	―	―
120 μg	32	0.952	0.026	0.075	0.036	0.0365
240 μg	36	0.942	0.024	0.065	0.035	0.0628

ISSN: 1471-2369